Abstract

Background: 17β-estradiol (E2) has been implicated to exert neuroprotective effects in the brain following cerebral ischemia. Classically, E2 is thought to exert its effects via genomic signaling mediated by interaction with nuclear estrogen receptors. However, the role and contribution of extranuclear estrogen receptors (ER) is unclear and was the subject of the current study.

Methodology/Principal Findings: To accomplish this goal, we employed two E2 conjugates (E2 dendrimer, EDC, and E2-BSA) that can interact with extranuclear ER and exert rapid nongenomic signaling, but lack the ability to interact with nuclear ER due to their inability to enter the nucleus. EDC or E2-BSA (10 μM) was injected icv 60 min prior to global cerebral ischemia (GCI). FITC-tagged EDC or E2-BSA revealed high uptake in the hippocampal CA1 region after icv injection, with a membrane (extranuclear) localization pattern in cells. Both EDC and E2-BSA exerted robust neuroprotection in the CA1 against GCI, and the effect was blocked by the ER antagonist, ICI182,780. EDC and E2-BSA both rapidly enhanced activation of the prosurvival kinases, ERK and Akt, while attenuating activation of the proapoptotic kinase, JNK following GCI, effects that were blocked by ICI182,780. Administration of an MEK or PI3K inhibitor blocked the neuroprotective effects of EDC and E2-BSA. Further studies showed that EDC increased p-CREB and BDNF in the CA1 region in an ERK- and Akt-dependent manner, and that cognitive outcome after GCI was preserved by EDC in an ER-dependent manner.

Conclusions/Significance: In conclusion, the current study demonstrates that activation of extranuclear ER results in induction of ERK-Akt-CREB-BDNF signaling in the hippocampal CA1 region, which significantly reduces ischemic neuronal injury and preserves cognitive function following GCI. The study adds to a growing literature that suggests that extranuclear ER can have important actions in the brain.

Introduction

17β-Estradiol (E2) has been implicated to be neuroprotective against a variety of neurodegenerative disorders, including stroke, Alzheimer’s disease and Parkinson’s disease, although controversy exists [1]. For instance, a number of studies have documented that women are “protected” against stroke relative to men – at least until the years of menopause, when E2 levels decline. Intriguingly, stroke outcome in postmenopausal women has been shown in several studies to be worse as compared to males, with postmenopausal women having a significantly higher disability and mortality rate as compared to men [2,3,4,5]. While there may be many reasons for the worse stroke outcome in women, it is interesting that the onset and diminished outcome of stroke in women parallels the time period of falling E2 levels that occurs after menopause. Numerous studies have shown that exogenous administration of E2 dramatically reduces infarct volume following focal or global cerebral ischemia in ovariectomized female mice, rats and gerbils, and in male rats and gerbils [1,6,7,8,9,10]. Two estrogen receptor (ER) isoforms have been identified to date, ERα and ERβ, both of which are expressed in the adult brain and thus could mediate the neuroprotection by E2 [1,11,12]. ERα has been implicated as particularly important in the neuroprotective effects of E2, as evidenced by the fact that E2-mediated neuroprotection against middle cerebral artery occlusion (MCAO)-induced cerebral ischemia is lost in OVX ERα knockout mice, but not ERβ-
KO mice [13,14], and by the fact that ER$\alpha$, but not ER$\beta$, antisense oligonucleotides significantly attenuate E2 neuroprotection in the hippocampal CA1 region following global cerebral ischemia (GCI) [15]. However, use of purported selective ER$\alpha$ and ER$\beta$ agonists in the GCI model, suggested that both ER subtypes may contribute to E2 neuroprotection in the hippocampal CA1 region of the brain [16].

It has been predominantly thought that E2 neuroprotection in the brain is mediated principally by the “classical” nuclear ER-mediated genomic signaling pathway, which involves E2 interaction with nuclear ER and regulation of transcription of various genes that mediate neuroprotection. For instance, E2 has been shown to increase the expression of the anti-apoptotic gene, bel-2, in the ischemic penumbra following MCAO and global ischemia [17]. E2 also increases bel-2 in vitro in rat hippocampal neurons and human NT2 neurons [18,19], while it inhibits expression of pro-apoptotic BAD (bel-2-antagonist of cell death) [17,18,19,20]. Additionally, E2 enhances expression of the antiapoptotic prosurvival factor, survivin in the hippocampus CA1 following GCI, which facilitates neuronal survival [6]. E2 has also been shown to enhance expression of brain derived neurotrophic factor (BDNF) in the brain, which has been implicated as a neuroprotective factor and to be important for synaptic plasticity, learning, and memory [21,22].

In addition to genomic signaling, there is increasing evidence that rapid nongenomic signaling via membrane localized extranuclear ER may also play a role in mediating E2 neuroprotective effects in the brain [23,24,25]. Along these lines, several laboratories have shown that the rapid activation of extracellular signal-regulated kinases 1,2 (ERKs) by E2 is critical for its neuroprotective effects, as administration of a MEK inhibitor blocks E2 neuroprotection in neurons in vitro [24,25,26]. Furthermore, E2-induces ERK activation in the CA1 region after GCI, which is critical for its neuroprotective effects as treatment with a MEK inhibitor blocked E2-induced ERK activation and E2 neuroprotection in the hippocampus [27] Likewise, a role for the prosurvival serine kinase Akt in E2 neuroprotection has been implicated, as E2 rapidly up-regulates Akt activation in cortical neurons in vitro [28], and in the hippocampus CA1 in vivo following GCI [29], while treatment with a PI3K inhibitor attenuates the neuroprotective effects of E2 both in vitro and in vivo [28,29]. In addition, we recently demonstrated that E2 attenuates the rapid activation of the proapoptotic signaling kinase, JNK in the hippocampal CA1 region after GCI [6]. As a whole, these findings suggest that E2-induced rapid nongenomic signaling may play a critical role in E2 neuroprotection.

However, since the above studies principally used E2, which can activate both extranuclear and nuclear estrogen receptors, it has been difficult to distinguish the importance and contribution of extranuclear receptor-mediated signaling in E2 neuroprotective effects. To address this issue, the current study employed two E2 conjugates, E2-BSA conjugate [30,31,32] and the newer E2 dendrimer conjugate (EDC) [33], which due to their size and charge cannot enter the cell nucleus. EDC and E2-BSA retain their ability to induce rapid extranuclear-mediated nongenomic signaling, but lack significant nuclear ER-mediated genomic signaling ability due to their inability to enter the cell nucleus and interact with nuclear ER [32,33]. Thus, their use has the potential to provide important insight into the role and importance of extranuclear estrogen receptors in E2 neuroprotective effects in cerebral ischemia. The results of our study reveal that EDC and E2-BSA administered intracerebroventriculally (icv) rapidly activates ERK, Akt and CREB signaling pathways in the hippocampus, enhances levels of the CREB transcriptional target, brain-derived neurotrophic factor (BDNF), strongly protects the hippocampal CA1 region against neuronal cell death, and significantly improves hippocampal-dependent cognitive function in the Morris water maze following GCI. The study thus provides important new evidence of a critical role for extranuclear estrogen receptor activation in estrogen-induced neuroprotection and improved functional cognitive outcome following GCI, and suggests that ERK-Akt-CREB-BDNF signaling is an important component mediating extranuclear estrogen receptor beneficial neural effects.

Materials and Methods

Materials

Rabbit polyclonal anti-p-Akt1 (Ser47, sc-7985-R), anti-p-JNK (Thr183/Tyr185, sc-12882-R), anti-JNK (sc-572), anti-ACT (sc-10731), goat polyclonal anti-Akt (sc-7126), and anti-ERK (sc-94-G) antibodies were acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit anti-p-ERK1/2 (pTpY185/187, 44-680G) was from Biosource (Camarillo, CA, USA). Mouse monoclonal anti-NeuN (MAB377) was acquired from Millipore (Billerica, MA, USA). Rabbit p-CREB (Ser133, #9189) and mouse CREB (#9104) were from Cell Signaling Technology (Beverly, MA, USA). The secondary antibodies used were goat anti-rabbit IgG, goat anti-mouse IgG, and donkey anti-goat IgG and were from Sigma Chemical Co. (St. Louis, MO, USA). Dimethylsulfoxide (DMSO) was also from Sigma. Alexa Fluor 594 donkey anti-mouse IgG (A21203), Alexa Fluor 488 donkey anti-rabbit IgG (A21206) and Alexa Fluor 488 donkey anti-goat IgG (A11055) were purchased from Invitrogen (Carlsbad, CA, USA). PD98059, LY 294,002 and ICI 182,780 were purchased from Tocris Cookson, Inc (St. Louis, MO, USA). NBT/BCIP was obtained from Promega Corporation (Madison, WI, USA).

Methods

Global cerebral ischemia. Adult Sprague Dawley female rats weighing 250-300g were used throughout the study. All procedures were approved by the Medical College of Georgia institutional committee for care and use of animals and were in accordance with National Institutes of Health guidelines. The rats were bilaterally ovarioctomized under anesthesia, and one week later four-vessel occlusion (4-VO) cerebral ischemia was carried out. Briefly, under anesthesia with chloral hydrate (350 mg/kg, i.p.), vertebral arteries were permanently electrocauterized with a monopolar coagulator through the alar foramen of the first cervical vertebra. Common carotid arteries were exposed through the ventral midline cervical incision and ligatures were placed loosely around each artery without interrupting the carotid blood flow. On the next day, under light halothane anesthesia, the common carotid arteries were re-exposed and occluded with aneurysm clips to induce forebrain ischemia. After 10 min ischemia, blood flow was restored by releasing the clips. Criteria for forebrain ischemia were: completely flat electroencephalographs, maintenance of dilated pupils, absence of a cornea reflex when exposed to strong light stimulation, and maintenance of rectal temperature at about 37°C. Those not matching the criteria or with seizures were excluded. Sham animals received the same surgical procedures except bilateral carotid arteries were not occluded.

Morris water maze test. The spatial learning and memory of the rats were evaluated by Morris water maze as described previously [34,35]. The maze consisted of black circular pool (diameter 2.14 m, height 80 cm, filled with water at 21–22°C to a height of 50 cm). The pool was divided into four zones by the software with a hidden platform (9 cm in diameter, 1.5–2.0 cm below the water line) placed in one of the zones. The rat was
placed in the water facing the wall at one random start location of four (north, south, east and west, locating at equal distances from each other on the pool rim). Each rat was allowed to find the submerged platform within 90s, and rest on it for 20s. If the rat failed to find the hidden platform within 90s, it was placed on the platform for 20s. The procedure was repeated for all the four start locations. The latency time, representing the average of the four trials, to reach the platform and distance were recorded. Two sessions of four trials were conducted on the first testing day, and the interval was 4h. The first session was considered as training procedure. The second was formal testing and was conducted daily on the next 2 days. Four hours after the last trial, a probe trial was performed within 90s in which the platform was removed from the tank. The rat was placed in the water at the same random start location, and time spent in the quadrant of the pool, which previously contained the platform were used to assess performance of learning and memory of the rats.

Sample preparation. The rats were sacrificed under anesthesia at 10, 30min, 3h, 6h or 1 day after ischemia. The hippocampal CA1 region was micro-dissected from both sides of the hippocampal fissure at 0°C and quickly frozen in liquid nitrogen. Tissues were homogenized in a 1:10 (w/v) ice-cold homogenization buffer for 10 min consisting of 50 MOPS (mM, pH 7.4), 150 NaCl, 20 β-glycerophosphate, 3 DTT, 2 Na3VO4, 1 EGTA, 1 EDTA, 1 NaF, 1% Triton X-100, 1% NP-40 and inhibitors of proteases and enzymes (0.5 mM PMSF, 10 μg/ml each of aproatin, leupepin, and pepstatin A). This was followed by centrifugation at 15,000g for 15 minutes. The supernatant was removed and stored at −80°C until use. The protein concentrations were determined using a BCA protein assay kit with bovine serum albumin (BSA) as standard.

Western blotting. 100 μg protein of each sample was heated at 100°C for 5min with loading buffer containing 0.125 M Tris-HCL (PH 6.8), 20% glycerol, 4% SDS, 10% mercaptoethanol and 0.002% bromphenol blue, then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10% acrylamide gels. The proteins were transferred onto PVDF membranes (pore size, 0.45 μm). Blotting membranes were incubated with 3% BSA in TBST (10 mmol/L Tris (PH 7.5), 150 mmol/L NaCl, 0.05% Tween-20) and probed with corresponding primary antibodies at 4°C overnight. Use alkaline phosphatase conjugated monkey anti-goat IgG or goat anti-rabbit or rabbit anti-mouse IgG as secondary antibodies and BCIP/NBT as color substrate. The bands on the membranes were scanned and analyzed with an image analyzer (Labworks Software, UVP Upland, CA, USA). Phospho-protein signals were expressed as a ratio to the corresponding total protein, and the total proteins were expressed relative to actin in the same sample. Normalized means were then expressed relative to the ratio for sham-treated animals.

Histochmical analysis of neuroprotection. After 7 days of reperfusion period, the animals were deeply anesthetized with chloral hydrate and transcardially perfused with 0.9% saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). Brains were post-fixed in the same fixative at 4°C for 12h, cryoprotected in 30% sucrose in PB and then were cut longitudinally into 25μm sections with a cryostat. NeuN staining was performed as described previously by our laboratory [6,15]. Briefly, sections were washed with 0.1% PBS-Triton X-100 for 3×5min and permeabilized with 0.4% Triton X-100 in PBS for 5min. After incubation with blocking solutions containing 10% normal donkey serum for 1h at room temperature in PBS containing 0.1% Triton X-100, sections were incubated in primary antibodies (mouse anti-NeuN, 1:200) for 48h at 4°C. Sections were washed for 3×10 min, followed by incubation with Alexa Fluor 594 donkey anti-mouse antibody (1:200) for 1h at room temperature. Sections were then washed for 4×5min with PBS-Triton X-100, then PBS, and finally with water, and mounted using water-based mounting medium. Images were captured on a Confocal Laser Scanning Microscope (Olympus FV1000). The number of NeuN-positive CA1 neurons per 1 mm length of the medial CA1 pyramidal cell layer was counted bilaterally in five sections per animal. Cell counts from the right and left hippocampus on each of the five sections were averaged to provide the mean value. A mean±SD was calculated from the data in each group and statistical analysis performed as described below.

Confocal Microscopy. Coronal sections were permeabilized using 0.4% Triton X-100-PBS for 10 min. Sections were then incubated for 30 min in 10% donkey serum, followed by overnight incubation at 4°C with primary antibodies - mouse anti-NeuN (1:200) and rabbit anti-p-Akt (1:50), or mouse anti-NeuN (1:200) and rabbit anti-p-ERK1/2 (1:50), or mouse anti-NeuN (1:200) and goat anti-p-JNK. Sections were then washed for 30 min in 0.1% Triton X-100-PBS and incubated with different secondary antibodies (Alexa Fluor 594 donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG or Alexa Fluor 488 donkey anti-goat IgG) at room temperature for 1 h, followed by a final wash for 30 min in PBS. Sections were placed on slides and covered with mounting medium containing antifading agents (Biodema; Thermo Fischer Scientific). Images were obtained using an Olympus FV1000 laser scanning confocal microscope.

Administration of drugs. EDC (10 μM in 5 μl saline), E2-BSA (10 μM in 5 μl saline), or vehicle were bilaterally infused into the lateral ventricles (from the bregma: anteroposterior, ±0.8 mm; lateral, 1.5 mm; depth, 3.5 mm) 60min before induction of GCI. The estrogen receptor antagonist ICI182,780 (50 μg), the MEK and PI3K inhibitors PD98059 (10 μg), LY294002 (25 μg) were infused in 5 μl 1% DMSO respectively were administered icv 10min prior to EDC or E2-BSA treatment. A volume of 1μl each was infused over 5 min. Following injection, the needle was left in situ for 3min. The same volume of 1% DMSO or saline served as vehicle control.

Statistical Analysis. Statistical analysis of the results was carried out by one-way analysis of variance (ANOVA), followed by the least significant (LSD) or Student-Newman-Keuls tests. In all cases, p<0.05 was considered significant. Data was expressed as mean±SD.

Results

Extranuclear/membrane localization of EDC and E2-BSA in hippocampal CA1 cells after icv injection and enhanced neuronal survival and cognitive outcome in EDC- and E2-BSA-treated rats following global cerebral ischemia (GCI)

Figure 1A shows localization of FITC-tagged EDC and E2-BSA conjugates in the hippocampal CA1 region at 60 min following icv injection in the lateral ventricle of ovariectomized female rats. As shown in Fig.1A (a), FITC-EDC and FITC-E2-BSA conjugates are heavily localized in the CA1 after icv injection, displaying a punctuate extranuclear/membrane pattern of localization. Figure 1A (b&c) shows the neuroprotective ability of EDC and E2-BSA administered icv 60 min prior to GCI. Examination of NeuN-positive cells at 7d after GCI revealed that Vehicle-treated animals that underwent 10-min GCI displayed a significant loss of NeuN-positive cells in the hippocampal CA1 region as compared to Sham controls. Intriguingly, the cell impermeable E2 conjugates, EDC and E2-BSA both exerted
robust neuroprotection against GCI, an effect that appeared to be mediated by ER, as pretreatment with the ER antagonist, ICI182,780 completely abolished the neuroprotective effect of both EDC and E2-BSA. We next examined the effect of EDC upon functional outcome following GCI by examining EDC effect upon spatial learning and memory in rats 7–9 days after reperfusion using the Morris water maze (Figure 1B, a–c). As shown in Figure 1B(a), Vehicle-treated animals that underwent GCI showed significantly higher latencies in finding the submerged platform on days 7–9 post stroke as compared to sham control rats. In contrast, EDC-treated rats had significantly decreased latencies to find the submerged platform on day 7–9 as compared to the Vehicle group, an effect that was significantly reversed by the ER antagonist ICI182,780. Furthermore, Figure 1B(b) shows that Vehicle-treated animals spent significantly less time in the quadrant where the submerged platform was located as compared to sham animals on Day 9. In contrast, EDC-treated rats spent significantly greater amount of time in the quadrant where the submerged platform was located as compared to Vehicle group, and this effect was significantly reversed by the ER antagonist, ICI182,780, suggesting ER mediation of the cognitive enhancing/preservation effect of EDC. Finally, representative sample paths for the various groups and treatments for the maze and probe trials at 9 days reperfusion are provided in Figure 1B(c), which illustrates that EDC-treated animals in the probe trials spent significantly more time in the quadrant where the platform was located.

EDC and E2-BSA neuroprotective effects against GCI are mediated by ERK and Akt signaling pathways

\( p\text{-Akt} \) Fig. 3A–D. We next examined the extranuclear/membrane signaling pathways regulated by EDC and E2-BSA, with a focus on two known pro-survival kinases, Akt and ERK, and a pro-death kinase, JNK. As shown in Figure 2A–B, a time course study revealed that \( p\text{-Akt} \) levels in the CA1 increased slightly but significantly from 10min - 6h following reperfusion, with a fall back to sham levels at 1d reperfusion. Total Akt and \( \beta\text{-actin} \) levels did not change at any time point. EDC treatment led to a significant elevation of \( p\text{-Akt} \) levels in the CA1 from 10min - 3h, with a fall back to sham levels at 1d. Figure 2C shows that E2-BSA similarly enhances \( p\text{-Akt} \) levels at 10 min after reperfusion following GCI, while total Akt levels were unchanged. Figure 2D shows representative double immunohistochemistry results for NeuN and \( p\text{-Akt} \) in the CA1 region at 10 min reperfusion after GCI. The results mirror the Western blot results observed in Figure 2A, with 10 min reperfusion increasing \( p\text{-Akt} \) levels slightly, with a more robust increase of \( p\text{-Akt} \) staining observed following EDC and E2-BSA treatment. Note also the \( p\text{-Akt} \) induction is colocalized with NeuN, suggesting that the elevation of \( p\text{-Akt} \) by EDC and E2-BSA occurs in neurons in the hippocampal CA1 region.

\( p\text{-ERK} \) Fig. 3A–D shows the effect of EDC and E2-BSA upon \( p\text{-ERK} \) levels in the CA1 region after GCI. As shown in Figure 3A–B, reperfusion had a biphasic elevation of \( p\text{-ERK} \) levels in the CA1 after GCI, with an initial 2-fold increase over sham observed at 10min, followed by a fall back to sham levels from 3h–6h, and a second elevation of \( p\text{-ERK} \) at 1d. It should be noted that \( p\text{-ERK1} \) and \( p\text{-ERK2} \) changed in parallel in our study, and that total \( ERK \) levels showed no change at any timepoint. EDC treatment significantly increased \( p\text{-ERK} \) levels in the CA1 region from 10 min - 6h, as compared to the reperfusion or vehicle control. Figure 3C shows that E2-BSA has a similar enhancing effect upon \( p\text{-ERK} \) levels in the CA1 region at 10min reperfusion following GCI. Confocal analysis of double immunohistochemistry for NeuN and \( p\text{-ERK} \) confirmed the Western blot results, demonstrating that EDC and E2-BSA markedly enhance \( p\text{-ERK} \) levels in the CA1 at 10min reperfusion after GCI, with the increase in \( p\text{-ERK} \) occurring in CA1 neurons (Figure 3D).

\( p\text{-JNK} \) We next examined EDC and E2-BSA upon activation of JNK, a proapoptotic factor. Figure 4A–B shows that \( p\text{-JNK} \) levels are increased at all times after reperfusion as compared to sham, except for the 3h time point which was not significantly elevated. Total JNK levels did not change regardless of time or treatment. EDC significantly inhibited \( p\text{-JNK} \) levels at all time points following GCI, except the 3h time point where \( p\text{-JNK} \) levels were not elevated following reperfusion. E2-BSA also significantly inhibited the elevation of \( p\text{-JNK} \) at 10min after reperfusion, while having no effect upon total JNK levels (Figure 4C). Confocal analysis of NeuN and \( p\text{-JNK} \) double immunostaining confirmed the EDC and E2-BSA attenuation of \( p\text{-JNK} \) elevation at 10min reperfusion following GCI, and further demonstrated that the elevation of \( p\text{-JNK} \) occurred predominantly in CA1 neurons, although some non-NeuN positive cells also showed \( p\text{-JNK} \) staining as well (Figure 4D).

**Inhibition of ERK and PI3K-Akt Signaling Abolishes EDC and E2-BSA Neuroprotection.** We next examined the role of ERK and PI3K-Akt signaling in mediating EDC and E2-BSA neuroprotection following GCI. Figure 5A shows that EDC and E2-BSA enhancement of \( p\text{-ERK} \) levels in the CA1 region at 10min reperfusion after GCI is abolished by pretreatment with the MEK inhibitor, PD98059. Likewise, pretreatment with the PI3K inhibitor, LY294002 markedly attenuated the ability of EDC and E2-BSA to enhance \( p\text{-Akt} \) levels in the CA1 region at 10min reperfusion after GCI (Figure 5B). A functional role for ERK and Akt signaling in EDC and E2-BSA neuroprotection against GCI is suggested by the findings in Figure 5C(a,b), in which pretreatment with PD98059 or LY294002 markedly attenuated EDC and E2-BSA neuroprotection, as demonstrated by NeuN staining in the hippocampal CA1 region. Furthermore, as shown in Figure 6, additional work suggests that EDC and E2-BSA regulatory effects upon ERK, Akt and JNK activation after GCI are mediated by estrogen receptors, as pretreatment with the ER antagonist,
ICI182,780 abolished EDC and E2-BSA modulation of ERK, Akt and JNK activation in the CA1 region at 10min reperfusion.

Activation of CREB and enhanced levels of BDNF by EDC following GCI

We next examined whether EDC could regulate activation of the transcription factor, CREB, and its transcriptional target BDNF in the hippocampal CA1 region after GCI. As shown in Fig. 7A, EDC rapidly increased pCREB levels in the CA1 region 10min post reperfusion, with a subsequent increase at 3h, 6h and 1d as compared to sham and vehicle controls. E2-BSA also increased pCREB levels similar to EDC at 10min post-reperfusion. The early elevation of pCREB levels by EDC, was followed by elevation of its transcriptional target, BDNF at latter
time points (6h and 1d reperfusion) in the hippocampal CA1 region. Fig. 7B&C illustrates the effect of the PI3K and MEK inhibitor on EDC enhancement of pCREB and BDNF levels in the hippocampal CA1 region at 10min and 6h after reperfusion. As shown in Fig 7B&C, administration of the PI3K or MEK inhibitor markedly attenuated EDC-induced pCREB elevation in the CA1 region at 10min and 6h after reperfusion, as well as significantly attenuated the EDC-induced BDNF elevation at 6h after reperfusion, suggesting that PI3K-Akt and MEK-ERK signaling pathways mediate the EDC-induced elevation of pCREB and BDNF in the hippocampus following GCI.

Discussion

The results of the current study provides evidence that activation of extranuclear estrogen receptors by E2 conjugates EDC and E2-BSA rapidly induces activation of a ERK-Akt-CREB-BDNF signaling pathway and results in neuroprotective
and cognitive preserving effects in the hippocampal CA1 region following GCI. Use of fluorescent-labeled EDC and E2-BSA conjugates confirmed that the conjugates exhibit an extranuclear/membrane localization pattern, and do not enter the nucleus after icv injection. Some cells also showed some cytoplasmic staining/localization of the E2 conjugates. This finding agrees with previous work in vitro demonstrating that the E2 conjugates localize principally to the membrane with some cytoplasmic localization and are unable to enter the nucleus and activate nuclear ER, but are potent activators of rapid membrane signaling pathways [32,33]. That the rapid signaling effects of EDC and E2-BSA observed in our study are mediated by estrogen receptors was evidenced by the fact that they were blocked by administration of the ER antagonist, ICI182,780.

Currently, it is unclear which extranuclear estrogen receptor mediates the rapid effects of E2 or the E2 conjugates used in our study. Work by Levin’s group [36,37] has shown that ERα and ERβ can exist as dimers in the plasma membrane of cells, and that COS-7 cells engineered to express ERα and ERβ display localization of ~2–5% of ERα and ERβ protein to the plasma membrane.

Figure 4. Effects of EDC and E2-BSA on phosphorylation level of JNK following cerebral ischemia in the hippocampal CA1 region. (A) Time courses of p-JNK and JNK, as well as the effects of EDC. Rats were subjected to 10min ischemia followed by 10min, 30min, 3h, 6h and 1d reperfusion. Bands corresponding to p-JNK were scanned and the intensities represented as values are showed in (B). F(11,36) = 24, *p<0.05 vs. sham; F(11,36) = 24, #p<0.05 vs. Vehicle. (C) Effect of E2-BSA on p-JNK at 10min of reperfusion. F(3,12) = 9, *p<0.05 vs. sham; F(3,12) = 9, #p<0.05 vs. Vehicle. (D) Confocal analysis of NeuN and p-JNK immunostaining in hippocampus CA1 at 10min reperfusion after global cerebral ischemia. Sham(a,b,c); vehicle(d,e,f); R10min+EDC(g,h,i); R10min+E2-BSA(j,k,l). Magnification 40× and Scale bar 50μm.
doi:10.1371/journal.pone.0009851.g004
membrane [32]. These studies suggest that classical ERs can be targeted to the plasma membrane. Additional work demonstrated that palmitoylation of ERα and ERβ and interaction with the scaffold protein, caveolin-1, are key mechanisms for targeting ERα and ERβ to the plasma membrane [38,39]. These studies were conducted in non-neuronal cells, however, western blot, immunohistochemical and surface biotinylated protein studies have confirmed the presence of both ERα and ERβ at the plasma membrane of neurons in the in various brain regions including the hippocampus, and at other extranuclear sites, such as in dendrites and spines [40,41,42,43,44,45,46]. Furthermore, membrane localization of ERα and ERβ has been demonstrated in glia cells in different brain regions [43,45,47,48], and glia cells have also been implicated to participate in mediating estrogen neuroprotection via the release of growth factors and neuroactive steroids [49,50,51]. While in our study, we did not perform GFAP staining to determine whether astroglial cells had FITC-EDC membrane labeling, we did observe some cells in the hippocampus with typical glia morphology that displayed FITC-EDC membrane labeling. Thus, this supports the possibility that E2 may also act on glial cells to facilitate its neuroprotective protective effects, as suggested by others previously [49,50,51]. However, the role of

**Figure 5. Effects of PD98059 and LY294002 on neuroprotective role by E2-BSA and EDC following cerebral ischemia in hippocampal CA1 region.** (A) Effects of PD on p-ERK1/2 level at 10min of reperfusion in rats pre-treated with EDC or E2-BSA. F(4,15) = 121, *p*<0.001 vs. sham; F(4,15) = 121, *p*<0.001 vs. Vehicle. (B) Effects of LY on p-Akt level at 10min of reperfusion in rats pre-treated with EDC or E2-BSA. F(4,17) = 54, *p*<0.001 vs. sham; F(4,17) = 54, *p*<0.05 vs. Vehicle. (C) NeuN immunostaining showed the effects of PD or LY on surviving neurons of the hippocampal CA1 region in rats treated with EDC or E2-BSA and subjected to 10min ischemia followed by 7d reperfusion (Fig. 5C, panel a). NeuN-positive neurons in per 1mm length of CA1 region was counted as vital survival neurons as shown in Fig. 5C, panel b. F(7,32) = 68, *p*<0.001 vs. vehicle group; F(7,32) = 68, *p*<0.001 vs. groups pre-treated with EDC or E2-BSA. PD: PD98059, LY: LY294002, Veh: vehicle.

doi:10.1371/journal.pone.0009851.g005
ERβ, as the antisense knockdown only achieved a 50–60% knockdown of the ERβ protein in that study and a greater reduction may be needed to determine conclusively a role or non-role of ERβ. However, use of ER knockout mice revealed that E2 neuroprotection in focal cerebral ischemia was unaffected by complete whole animal knockout of ERβ, while, in contrast, ERα knockout mice had a dramatic loss of E2 neuroprotection [15], further supporting a critical role for ERα in E2 neuroprotective effects. Finally, it is also possible that the newly identified putative G-protein-coupled estrogen receptor, GPR30, could have a role in mediating E2 rapid signaling and neuroprotective effects [53,54]. In support of this possibility, preliminary studies by our lab found that i.c.v administration of antisense oligonucleotides to GPR30 significantly attenuated E2 rapid signaling and neuroprotection following GCI (unpublished observations). Thus, in addition to extranuclear ERα, extranuclear GPR30 may also participate in mediating estrogen rapid signaling and neuroprotective effects in the hippocampus. Interestingly, studies in pancreatic beta cells similarly revealed a role for both extranuclear ERα and GPR30 in mediating E2 protection of pancreatic beta cells from streptozotocin-induced apoptosis [55].

While our data demonstrates a potent effect of EDC (and E2-BSA) in inducing rapid nongenomic signaling, one should not construe that EDC only activates a nongenomic signaling pathway and is incapable of exerting genomic effects. Work by Katzenellenbogen and coworkers [56] clearly showed that EDC could regulate gene expression in cells in vitro and that the effect did not involve interaction with or activation of nuclear ER genomic signaling. Rather, EDC effected changes in gene expression via its activation of rapid ERK and Src kinase signaling which can regulate phosphorylation of transcription factors, histones and other factors and thereby modulate gene transcription. The study further showed that EDC was incapable of recruiting nuclear ERα to estrogen responsive regions of genes, whereas ERα recruitment by E2 was very effective. Thus, EDC nongenomic signaling can induce genomic signaling that is independent of nuclear ER. Intriguingly, previous work by Pfaff and coworkers has also demonstrated that nongenomic signaling by E2 in the hypothalamus can actually potentiate E2 genomic actions to induce lordosis behavior [57,58], suggesting that rapid effects of E2 may also modulate genomic effects of E2.

Interestingly, our own findings revealed that EDC and E2-BSA enhanced phosphorylation of the transcription factor, CREB in a rapid fashion following reperfusion, and that this effect is ERK- and Akt-dependent. Among the best known CREB transcriptional targets is the growth factor, BDNF, which was shown in our study to also be elevated by EDC. We also found that a second transcriptional target of CREB, Bel-2, a potent antiapoptotic factor, was also induced by EDC in the hippocampal CA1 region following ischemic reperfusion (unpublished observation). These findings raise the possibility that EDC activation of extranuclear estrogen receptors may involve a nongenomic to genomic signaling cascade via kinase-induced activation of the transcription factor, CREB. It should be noted that Etgen and coworkers [59] previously demonstrated that E2 rapidly elevates pCREB in the hippocampal CA1 following GCI, while Raval et al [60] found that higher serum E2 levels on proestrus was correlated with increased pCREB in the hippocampus and increased neuroprotection from GCI, further supporting a potentially critical role for CREB in E2 neural actions. Our study adds to these findings by demonstrating a role for extranuclear estrogen receptors in CREB activation via the use of the nuclear impermeable E2 conjugates, demonstrating the importance of ERK and Akt signaling for CREB activation and for elevation of BDNF, and demonstrating a
In addition to enhancing activation of the well-known pro-survival factors, ERK, Akt and CREB, our study demonstrated that EDC exerted a prolonged attenuation of phosphorylation of JNK at Thr183/Tyr185, phosphorylation sites known to be critical for JNK activation [61]. JNK is known to phosphorylate many cellular proteins, including several implicated in apoptosis, and can translocate to the nucleus to activate c-Jun and AP-1-mediated gene transcription, leading to transcription of pro-death genes [62]. Previous work by our group and others has shown that administration of a JNK inhibitor [6,63] or knockout of JNK [64] results in profound protection of the brain against cerebral ischemia, further demonstrating a key pro-apoptotic role of JNK in ischemic neuronal cell death. Thus, the ability of EDC to markedly attenuate JNK activation after GCI likely contributes significantly to its neuroprotective actions.

Finally, with respect to the cognitive preserving effects of EDC, it is suggested that EDC activation of CREB and its ability to increase BDNF in the hippocampal CA1 region likely plays a significant role in preservation of cognitive function following GCI. Both CREB and BDNF have been implicated in neuroprotection, as well as in facilitating learning and memory [21,65,66,67,68,69]. It should be noted that the enhanced expression of BDNF by EDC was delayed in our study as compared to the CREB activation, as BDNF elevation occurred at 6–24h after reperfusion, while pCREB elevation occurred as early as 10min post-reperfusion. The delayed induction of BDNF could be explained by the time needed for CREB to enhance transcription.
of BDNF and for its translation into mature protein. The importance, as prolonged CREB activation has been correlated with enhanced neuroprotection in previous studies [65,70].

 actions that reduce ischemic neuronal cell death in the hippocampal CA1 region following GCI and thereby preserves cognitive function. However, BDNF has also been implicated to regulate synaptic plasticity [69], and such a plasticity-regulatory action in the early post-ischemic reperfusion period (first 24h) could help maintain synaptic connections following the ischemic insult, which also could facilitate preservation of cognitive function.

 In conclusion, the current study provides important new evidence that activation of extranuclear estrogen receptors with resultant induction of an ERK-Akt-CREB-BDNF signaling pathway mediates neuroprotection and preservation of cognitive function following GCI. The study thus adds to a growing literature supporting a potentially important role of extranuclear estrogen receptors in mediating estrogen beneficial effects in the brain.

 Author Contributions

 Concealed and designed the experiments: QGZ FY RmW DB. Performed the experiments: LeY QGZ Ciz Ydz RmW. Analyzed the data: LeY QGZ Ciz FY Ydz RmW DB. Wrote the paper: QGZ RmW DB.

 References

 1. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM (2007) Neurotrophin and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 72: 391–405.
 2. Murphy SJ, McCullough LD, Smith JM (2004) Stroke in the female: role of biological sex and estrogen. ILAR J 45: 147–159.
 3. Nejad-Meisami M, Kobashi A, Sandzerek PA, Czlonkowska A (2005) Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the international stroke trial. Neuroepidemiology 24: 123–128.
 4. Di Carlo A, Lamassa M, Baldreschi M, Pracucci G, Basile AM, et al. (2003) Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke 34: 1114–1119.
 5. Roquer J, Campoello AR, Gomis M (2003) Sex differences in first-ever acute stroke. Stroke 34: 1351–1358.
 6. Zhang QG, Wang R, Khan M, Mahesh V, Brann DW (2008) Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. J Neurosci 28: 8430–8441.
 7. Simpkins JW, Rajakumar G, Zhang YQ, Simpkins CE, Greenwald D, et al. (1997) Estrogens may reduce mortality and ischemic damage caused by midline cerebral artery occlusion in the female rat. J Neurosci 17: 724–730.
 8. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, et al. (1998) Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 18: 1253–1261.
 9. Shughrue PJ, Merchenthaler I (2003) Estrogen prevents the loss of CA1 hippocampal neurons in gerbils after ischemic injury. Neuroscience 116: 851–861.
 10. Zhang QG, Shu J, Rajakumar G, Day AL, Simpkins JW (1998) Effects of gender and estradiol treatment on focal brain injury. Brain Res 784: 321–324.
 11. Deroz BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116: 561–570.
 12. McEwen BS (2001) Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 91: 2785–2801.
 13. Dubal DB, Zhu H, Yu J, Rao SW, Shughrue PJ, et al. (2001) Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A 98: 1952–1957.
 14. Merchenthaler I, Dellowe TL, Shughrue PJ (2003) Neuroprotection by estrogen in animal models of global and focal ischemia. Ann N Y Acad Sci 1007: 89–100.
 15. Zhang QG, Raz L, Wang R, Han D, De Sevilla L, et al. (2009) Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci 29: 13823–13836.
 16. Miller NR, Jover T, Cohen HW, Zoukin RS, Engen AM (2005) Estrogen can act via estrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death. Endocrinology 146: 3070–3079.
 17. Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM (1999) Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci 19: 6355–6365.
 18. Wu JW, Wang X, Chen S, Braun RD (2005) 17beta-estradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-AMP response element binding protein signal pathway and Bcl-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced neuroprotection. J Neurosci 25: 59–72.
 19. Zhao L, Brinton RD (2007) Estrogen receptor alpha and beta differentially regulate intracellular Ca2+ dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res 1172: 48–59.

 20. Alkayed NJ, Goto S, Sugo N, Jol HD, Klauss J, et al. (2001) Estrogen and Bcl-2: gene induction and effect of transgene in experimental stroke. J Neurosci 21: 7543–7550.
 21. Bekinschtein P, Cammarota K, Katche C, Slipczuk L, Rossatto JH, et al. (2008) BDNF is essential to promote persistence of long-term memory storage. Proc Natl Acad Sci U S A 105: 2711–2716.
 22. Nakajo Y, Miyamoto S, Nakano Y, Xue HJ, Horii T, et al. (2000) Genetic increase in brain-derived neurotrophic factor levels enhances learning and memory. Brain Res 1214: 103–109.
 23. Raz L, Khan MM, Mahesh VR, Vadlamudi RK, Brann DW (2008) Rapid estrogen signaling in the brain. Neurosignals 16: 140–153.
 24. Singh M (2001) Ovarian hormones elicit phosphorylation of Akt and extracellular-signal-regulated kinase in explants of the cerebral cortex. Endocrinology 14: 407–415.
 25. Singh M, Setal G, Jr., Guan X, Warren M, Toran-Allerand CD (1999) Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 19: 1179–1189.
 26. Singer CA, Figueroa-Masot MA, Batchelor RH, Dorsa DM (1999) The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 19: 2453–2463.
 27. Jover-Mengual T, Zoukin RS, Engen AM (2007) MAPK signaling is critical to estradiol protection of CA1 neurons in global ischemia. Endocrinology 148: 1131–1143.
 28. Choi YC, Lee JH, Hong KW, Lee KS (2004) 17 Beta-estradiol prevents focal cerebral ischemic damages via activation of Akt and CREB in association with reduced PTEN phosphorylation in rats. Fundam Clin Pharmacol 18: 547–557.
 29. Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, et al. (2006) Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. Brain Res 1078: 1086–1090.
 30. Tajuchi Y, Kosowski M, Bodenner DL (2004) Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl Recept 2: 5.
 31. Aguilà R, Bellido C, Garrido-Gracia JC, Alonso R, Sanchez-Criado JE (2006) Estradiol and its membrane-impermeable conjugate estradiol-BSA inhibit taoxins-stimulated prolactin secretion in incubated rat pituitaries. Reproduction 131: 763–769.
 32. Razandi M, Pedram A, Greene GL, Levin ER (1999) Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of cERalpha and cERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 13: 307–319.
 33. Harrington WR, Kim SH, Funk CC, Madnak-Erdogan Z, Schiff R, et al. (2006) Estrogen desflurane conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20: 491–502.
 34. Soderstrom I, Strand M, Ingrihn AS, Nasic S, Olsson T (2009) 17beta-estradiol and enriched environment accelerate cognitive recovery after focal brain ischemia. Eur J Neurosci 29: 1215–1224.
 35. Morris R (1988) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.
 36. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER (2004) Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 18: 2854–2865.
 37. Hames SR, Levin ER (2007) Extraneural steroid receptors: nature and actions. Endocr Rev 28: 726–741.
 38. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, et al. (2007) A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 282: 22278–22288.
Estrogen Signaling

39. Ewing AJ, 3rd, Levin ER (2005) Requirements for estrogen receptor alpha membrane localization and function. Steroids 70: 361–363.

40. Kalita K, Szymczak S, Kaczmarek L (2005) Non-nuclear estrogen receptor beta and alpha in the hippocampus of male and female rats. Hippocampus 15: 404–412.

41. Mihore TA, McEwen BS, Hayashi S, Li GJ, Reagan LP, et al. (2001) Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J Comp Neurol 429: 355–371.

42. Niinoh M, Kuroki Y, Watanabe Y (2004) Subcellular localization of estrogen receptor beta in mouse hippocampus. Neurosci Lett 355: 109–112.

43. Azcoitia I, Sierra A, Garcia-Segura LM (1999) Localization of estrogen receptor beta-immunoreactivity in astrocytes of the adult rat brain. Glia 26: 260–267.

44. Gorruso S, Lorenzo AG, Cambiasso MJ (2006) Estrogen receptor alpha is expressed on the cell-surface of embryonic hypothalamic neurons. Neuroscience 154: 1173–1177.

45. Marin R, Diaz M, Alonso R, Sanz A, Arevalo MA, et al. (2009) Role of estrogen in the hippocampus. Brain Res Brain Res Rev 48: 273–286.

46. Gorosito SV, Lorenzo AG, Cambiasso MJ (2008) Estrogen receptor alpha is expressed on the cell-surface of embryonic hypothalamic neurons. Neuroscience 154: 1173–1177.

47. Bondar G, Kuo J, Hamid N, Micevych P (2009) Estradiol-induced estrogen receptor beta-immunoreactivity in astrocytes of the adult rat brain. Glia 26: 260–267.

48. Kelly MJ, Ronnekleiv OK (2009) Control of CNS neuronal excitability by estradiol through membrane-initiated signaling. Mol Cell Endocrinol 308: 17–25.

49. Mumby TJ, McEwen BS, Hayashi S, Li GJ, Reagan LP, et al. (2001) Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J Comp Neurol 429: 355–371.

50. Dhandapani KM, Wade FM, Mahesh VB, Brann DW (2005) Astrocyte-derived transforming growth factor-β mediates the neuroprotective effects of estrogens via membrane-initiated signaling. Mol Cell Endocrinol 308: 17–25.

51. Azcoitia I, Sierra A, Garcia-Segura LM (1999) Localization of estrogen receptor beta-immunoreactivity in astrocytes of the adult rat brain. Glia 26: 260–267.

52. Nishio M, Kuroki Y, Watanabe Y (2004) Subcellular localization of estrogen receptor beta in mouse hippocampus. Neurosci Lett 355: 109–112.

53. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y (2006) G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 346: 904–910.

54. Garcia-Ovejero D, Azcoitia I, Garcia-Segura LM (1999) Localization of estrogen receptor beta-immunoreactivity in astrocytes of the adult rat brain. Glia 26: 260–267.

55. Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, et al. (2009) Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58: 2292–2302.

56. Madak-Erdogan Z, Kieser KJ, Kim SH, Kominn B, Katzenellenbogen JA, et al. (2000) Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 22: 2116–2127.

57. Yoshida T, Pfaff DW (2004) The membrane actions of estrogens can potentiate their lordosis behavior-facilitating genomic actions. Proc Natl Acad Sci U S A 101: 12334–12337.

58. Vaudevan N, Pfaff DW (2007) Membrane-initiated actions of estrogens in neuroendocineology: emerging principles. Endocr Rev 28: 1–19.

59. Lebesgue D, Chevaleyre V, Zukin RS, Egen AM (2005) Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection. Steroids 74: 555–561.

60. Raval AP, Saul I, Dave KR, DeFazio RA, Perez-Pinzon MA, et al. (2009) Pretreatment with a single estradiol-17β bolus activates cyclic-AMP response element binding protein and protects CA1 neurons against global cerebral ischemia. Neuroscience 160: 307–318.

61. Derijard B, Hills M, Wu H, Barrett T, Su B, et al. (1994) JNK: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025–1037.

62. Dhanasekaran DN, Reddy EP (2008) JNK signaling in apoptosis. Oncogene 27: 6243–6251.

63. Guan QH, Pui DS, Zhang QG, Hao ZB, Xu TL, et al. (2005) The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways. Brain Res 1035: 51–59.

64. Kuan CY, Whitmarsh AJ, Yang DD, Liao G, Schloemer AJ, et al. (2003) A critical role of neural-specific JNK3 for ischemic apoptosis. Proc Natl Acad Sci U S A 100: 15184–15189.

65. Walton MR, Dragunow M (2000) Is CREB a key to neuronal survival? Trends in Neurosciences 23: 48–53.

66. Silva AJ, 3rd, Levin ER (2005) The nuclear and non-nuclear pathways of CREB in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 1122: 130–143.

67. Porte Y, Buhot MC, Mons NE (2008) Spatial memory in the Morris water maze neuronal estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58: 2292–2302.

68. Kalita K, Szymczak S, Kaczmarek L (2005) Non-nuclear estrogen receptor beta and alpha in the hippocampus of male and female rats. Hippocampus 15: 404–412.

69. Lipsky RH, Marini AM (2007) Brain-derived neurotrophic factor in synaptic plasticity. Mol Cell Neurosci 42: 81–89.

70. Liu F-C, Graybiel AM (1996) Spatiotemporal Dynamics of CREB Phosphorylation: Transient versus Sustained Phosphorylation in the Developing Striatum. J Neurosci 16: 404–412.